

(SUMMARY TRANSLATION)

TSE Securities Code: 4565
2 June 2015

Shinichi Tamura
Board Director and CEO
Sosei Group Corporation
2-4 Kojimachi, Chiyoda-ku, Tokyo

To Shareholders:

Call for the 25th Ordinary General Meeting of Shareholders

The Company would like to inform you that the 25th Ordinary General Meeting of Shareholders will be held as follows, and would be grateful if you would attend the meeting.

Those who will not be able to attend the meeting on the day may exercise their voting rights in writing or via Internet. You are kindly requested to consider the appended "Reference Documents for the Ordinary General Meeting of Shareholders" and exercise your voting rights by indicating your approval or disapproval for each of the proposals. To be valid, the vote must reach the Company no later than 6:00 p.m. on Monday, 22 June 2015

Yours Sincerely,



Shinichi Tamura
Board Director and CEO

- 1. Date and Time** 10:00 a.m. on Tuesday, 23 June 2015
- 2. Venue** Fuji Higashi-No-Ma Hall, 4th Floor, Grand Arc Hanzomon Hotel
1-1, Hayabusa-cho, Chiyoda-ku, Tokyo, Japan
- 3. Meeting Agenda**

Items to be reported:

1. Business Report, Consolidated Financial Statements, Independent Auditor's Report and Audit Committee Report on Consolidated Financial Statements for the 25th fiscal year (from 1 April 2014 to 31 March 2015)
2. Financial Report for the 25th fiscal year (from 1 April 2014 to 31 March 2015)

Items to be resolved:

Resolution 1: Election of Five (5) Directors

Should any revision to the Reference Documents for the Ordinary General Meeting of Shareholders, Business Report, Financial Statements or Consolidated Financial Statements be made, the Company will inform you in writing, or via Company's website (<http://www.sosei.com/>).

Reference Documents for the Ordinary General Meeting of Shareholders

Resolution 1: Election of Five (5) Directors

The terms of office of all five (5) directors will expire upon the conclusion of the Ordinary General Meeting of Shareholders. In accordance with the decision of the Nomination Committee, the re-election of the following five (5) directors is proposed.

No.	Name (Date of birth)	Personal history		No. of shares owned
1	Shinichi Tamura (17 September 1949)	Apr.1978 Feb.1987 Jul.1989 Jun.1990 Jun.2005 Mar.2012	Joined Fujisawa Pharmaceuticals Inc. (now Astellas Pharma Inc.) Joined Genentech Inc. Representative Director of Genentech Ltd. Representative Director of the Company Director and Chief Executive Officer of the Company (to present) Managing Director of Sosei R&D Ltd. (to present) Company committees: Nomination Committee (member)	374,100
2	Takuya Fujii (5 July 1945)	Apr.1968 Jun.1974 Dec.1998 Mar.2001 Jan.2005 Jun.2005 Oct.2005	Joined the Bank of Japan Studied at Wharton School, Penn., U.S.A. (MBA degree) Chairman of Nippon Credit Bank Representative of Marsh & McLennan Companies in Japan Representative of F Business Brain External Director of the Company (to present) Representative President and CEO of Promontory Financial Group Global Service Japan, LLC (to present) Company committees: Nomination Committee (Chairman) Auditing Committee (member)	3,600

3	Dr. Declan Doogan (22 March 1952)	Feb.1978 Feb.1982 Feb.2005 Oct.2005 Jun.2007 Nov.2009 Sep.2010 Dec.2011 Dec.2012 Feb.2013 Jan.2014 Feb.2015	Joined DupharBV. Joined Pfizer Inc. Head of Worldwide Clinical Development of Pfizer Inc. Visiting Professor of Kitasato University (to present) External Director of the Company (to present) Interim CEO of Amarin Corporation plc ("Amarin") Chief Medical Officer of Amarin Chairman of Spinifex Pharmaceuticals (to present) Founder of Brain Food Inc (to present) Chairman of Portage Pharma Inc (to present) Executive Chairman of Biohaven Pharmaceutical Holding Company Limited (to present) Director of Heptares Therapeutics Ltd. (to present) Company committees: Compensation Committee (Chairman) Nomination Committee (member)	-
4	Peter Bains (26 July 1957)	Mar.1996 Jan.2000 Jan.2001 Jun.2009 Jan.2010 Apr.2010 Jun.2010 Jul.2013 Dec.2013 Jan.2015 Feb.2015 Mar.2015	General Manager of SmithKline and Beecham (present GlaxoSmithKline) Served as a core member of GlaxoWellcome and SmithKline Beecham M&A Senior Vice President of international commercial development of SmithKline and Beecham Director of Peter Bains Consulting Limited Non-executive Board Director of Syngene International Limited Non-executive Chairman of Fermenta Biotech Limited (to present) External Director of the Company (to present) Non-executive Director of Kromek Group PLC (to present) Non-executive Director of Minapharm Pharmaceuticals S.A.E. (to present) Non-executive Director of Phase4 Partners Ltd. (to present) Director of Heptares Therapeutics Ltd. (to present) Executive Director and CEO of Syngene International Limited (to present) Company committees: Compensation Committee (member) Auditing Committee (member)	-

5	Tomohiro Tohyama (21 February 1950)	Apr.1978	Entered the Legal Training and Research Institute of the Supreme Court of Japan	-
		Apr.1980	Registered with the Daiichi Tokyo Bar Association and joined Nishimura and Sanada Law Firm	
		May1984	Served in Mason & Sloane in the U.S.A.	
		Feb.1985	Served in Pollock, Bloom & Dekom in the U.S.A.	
		Jun.1985	Pryor, Cashman, Sherman & Flynn in the U.S.A.	
		Aug.1985	Re-joined Nishimura and Sanada Law Firm as a partner	
		Oct.1990	Co-founding partner of TMI Associates (to present)	
		Nov.1999	External auditor of Nippon Shikizai, Inc. (to present)	
		Jun.2010	External director of Avex Group Holdings Inc. (to present)	
Jun.2011	External Director of the Company (to present) Company committees: Auditing Committee (Chairman) Compensation Committee (member)			

Notes:

1. There are no specific conflict of interests between the candidates and the Company.
2. Mr. Takuya Fujii, Dr. Declan Doogan, Mr. Peter Bains, and Mr. Tomohiro Tohyama are candidates for external directors.
3. Reasons for the election of candidates for external directors:
The Company proposes the election of the candidates concerned based on the below and hereby confirms their independence:
 - 1) Regarding Mr. Takuya Fujii, the Company believes that by taking advantage of his extensive business experience and expertise in risk management, the management framework of the Company will be further enforced. His term of the office will have been ten years at the end of the Ordinary General Meeting of Shareholders. The Company designated him an independent director under the rules of the Tokyo Stock Exchange, and has notified the Exchange.
 - 2) Dr. Declan Doogan has headed the research and development department of the world biggest drug company including experience working in Japan. The Company believes that by taking advantage of his expertise and experience in the pharmaceutical research and development, the Company's management framework will be further enforced. His term of the office will have been eight years at the end of the Ordinary General Meeting of Shareholders.
 - 3) Mr. Peter Bains has engaged in building of global marketing strategies mainly in Asia at one of the world's pre-eminent drug companies, and has played an active part as a core member of a project for the merger of large scale leading drug companies. The Company believes that by taking advantage of his knowledge and experience, the business development of the Company will be further enforced. His term of the office will have been five years at the end of the Ordinary General Meeting of Shareholders.
 - 4) Mr. Tomohiro Tohyama has had no direct operational management experience of a company, but the Company believes that by taking advantage of his knowledge and

experience of engaging in international legal affairs, and as a partner of one of the leading law firms in Japan, the management and governance framework will be further enforced. His term of the office will have been four years at the end of the Ordinary General Meeting of Shareholders.

4. Liability limitation agreement with external directors:
 - 1) Pursuant to the provisions of Article 427-1 of the Company Act, the Company executed a liability limitation agreement set forth in Article 423-1 of the Company Act with each of Messrs. Takuya Fujii, Declan Doogan, Peter Bains and Tomohiro Tohyama. The maximum liability based on the mentioned agreement is the total minimum liability set forth in Article 425-1 of the Company Act.
 - 2) If the agenda is approved at the General Meeting of Shareholders, the Company will execute the same liability limitation agreement as referred to in preceding item 1) with each of Messrs. Takuya Fujii, Declan Doogan, Peter Bains and Tomohiro Tohyama.